An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma (TL139)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00685204|
Recruitment Status : Unknown
Verified May 2008 by Taxolog Inc..
Recruitment status was: Recruiting
First Posted : May 28, 2008
Last Update Posted : May 28, 2008
|Condition or disease||Intervention/treatment||Phase|
|Mesothelioma||Drug: Milataxel||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||90 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||A Phase II Study of Milataxel (TL139) Administered Orally in Patients With Malignant Mesothelioma|
|Study Start Date :||March 2008|
This is a non-random, multicenter, open label, single agent study. Patients with mailgnanat mesothelioma that has reccured or progressed following chemotherapy, and who qualify for this study, will receive oral milataxel.
Milataxel is a liquid that is dosed orally at 60 mg/m2 on Day 1 of a 21 day cycle. If no toxicities of greater than Grade 1 severity occur, patients will receive 75 mg/m2 for the second and subsequent cycles.
Other Name: TL139
- To determine the objective response rate of milataxel when given orally to previously treated patients with malignant mesothelioma.
- To evaluate time to progression, duration of tumor response and safety and tolerability of TL139 treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00685204
|Contact: Harvey Pass, M.D.||(212)firstname.lastname@example.org|
|United States, Illinois|
|Rush University Medical Center||Not yet recruiting|
|Chicago, Illinois, United States, 60612|
|Contact: Philip Bonomi, M.D. 312-942-3192 email@example.com|
|University of Chicago||Recruiting|
|Chicago, Illinois, United States, 60637|
|Contact: Sarah Mauro 773-834-3263 firstname.lastname@example.org|
|Principal Investigator: Hedy Kindler, M.D.|
|United States, New York|
|New York University Cancer Center||Recruiting|
|New York, New York, United States, 10016|
|Contact: Harvey Pass, M.D. 212-731-5414 email@example.com|
|Principal Investigator:||Harvey Pass, M.D.||New York University Cancer Center|